NanoViricides, Inc. (NYSE American: NNVC) announced it has received National Ethics Committee approval in the Democratic Republic of the Congo (DRC) for a Phase II clinical trial evaluating its NV-387 oral gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company is preparing to submit a Clinical Trial Application to the DRC regulatory agency, ACOREP, and noted that NV-387 drug product is already in the country for an upcoming Phase II Mpox trial, enabling rapid trial initiation if regulatory approval is received.
NanoViricides said NV-387 is the only orally administered Ebola treatment currently under consideration for clinical evaluation, offering potential advantages over infusion-based therapies in resource-limited outbreak settings. The company believes its broad-spectrum antiviral platform, designed to target host-cell features used by viruses, could provide a treatment option for Bundibugyo and other ebolaviruses that currently have no approved therapies or vaccines. The full press release is available at https://ibn.fm/MuxOe.
The approval marks a significant milestone for NanoViricides as it advances its lead drug candidate NV-387 into Phase II human clinical trials. The company’s nanoviricide technology is based on intellectual property licensed from TheraCour Pharma, Inc., and aims to create special purpose nanomaterials for antiviral therapy. NV-387 is designed as a broad-spectrum antiviral drug for respiratory viral infections, MPOX/smallpox, and even measles, with the Ebola trial representing a new application.
The DRC is currently facing an outbreak of the Bundibugyo ebolavirus, for which there are no approved therapies or vaccines. The oral formulation of NV-387 could be particularly advantageous in remote areas where intravenous treatments are difficult to administer. NanoViricides believes that its approach of targeting host-cell features could make NV-387 effective against multiple ebolavirus strains.
Investors can find the latest news and updates regarding NNVC in the company’s newsroom at https://ibn.fm/NNVC.
